Identification of the putative brain tumor antigen BF7/GE2 as the (De)toxifying enzyme microsomal epoxide hydrolase

Cancer Research

Volumn 60, Issue 5, 2000, Pages 1403-1409

  Kessler, Reto ^a   Hamou, Marie France ^a   Albertoni, Michele ^c   De Tribolet, Nicolas ^a   Arand, Michael ^c   Van Meir, Erwin G ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EMORY UNIVERSITY   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPOXIDE HYDROLASE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY AFFINITY; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTE; BRAIN MICROSOME; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; EPOXIDE HYDROLASES; GLIOMA; HUMANS; MICE; RATS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034161990     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Schnegg, J. F., Diserens, A. C., Carrel, S., Accolla, R. S., and de Tribolet, N. Human glioma-associated antigens detected by monoclonal antibodies. Cancer Res., 41: 1209-1213, 1981.
2. de Muralt, B., de Tribolet, N., Diserens, A. C. Stavrou, D., Mach, J. P., and Carrel, S. Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens. Eur. J. Cancer Clin. Oncol., 21: 207-216, 1985.
3. de Muralt, B., de Tribolet, N., Diserens, A. C., Carrel, S., and Mach, J. P. Reactivity of antiglioma monoclonal antibodies for a large panel of cultured gliomas and other neuroectoderm derived tumors. Anticancer Res., 3: 1-6, 1983.
4. de Tribolet, N., Carrel, S., and Mach, J. P. Brain tumor-associated antigens. Prog. Exp. Tumor Res., 27: 118-131, 1984.
5. Schreyer, M., Hamou, M-F., Carrel, S., Mach, J-P., and de Tribolet, N. Immunohistological localization of glioma and melanoma-associated antigens with monoclonal antibodies. In: G. E. J. Staal and C. W. M. van Veelen (eds.), Markers of Human Neuroectodermal Tumors, pp. 53-62. Boca Raton: CRC Press, Inc., 1986.
6. Krajewski, S., Schwendemann, G., Weizsacker, M., Wechsler, W., and de Tribolet, N. Binding specificity of two monoclonal antiglioma antibodies: immunocytochemical studies using a new tissue embeddine technique. Acta Neuropathol., 69: 124-131, 1986.
7. Carrel, S., de Tribolet, N., and Mach, J. P. Expression of neuroectodermal antigens common to melanomas, gliomas, and neuroblastomas. I. Identification by monoclonal anti-melanoma and anti-glioma antibodies. Acta Neuropathol., 57.-158-164, 1982.
8. Wixtrom, R. N., and Hammock, B. D. Membrane-bound and soluble fraction epoxide hydrolases. In: D. Zakim and D. A. Vessey (eds.), Biochemical Pharmacology and Toxicology, Vol. 1, pp. 4-93. New York: John Wiley and Sons, 1985.
9. Thomas, H., Timms, C. W., and Oesch, F. Epoxide hydrolases: molecular properties, induction, polymorphisms and function. In: K Ruckpaul and H. Rein (eds.), Frontiers in Biotransformation, Vol. 2, pp. 280-329. Berlin: Akademie Verlag, 1990.
10. Seidegard, J., and DePierre, J. W. Microsomal epoxide hydrolase. Properties, regulation and function. Biochim. Biophys. Acta, 695: 251-270, 1983.
11. Oesch, F. Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica, 3: 305-340, 1973.
12. Lu, A. Y. H., and Miwa, G. T. Molecular properties and biological functions of microsomal epoxide hydrase. Annu. Rev. Pharmacol. Toxicol, 20; 513-531, 1980.
13. Van Meir, E. G., Sawamura, Y., Diserens, A-C., Hamou, M-F., and de Tribolet, N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res., 50: 6683-6688, 1990.
14. Albertoni, M., Daub, D. M., Arden, K. C., Viars, C. S., Powell, C., and Van Meir, E. G. Genetic instability leads to loss of both p53 alleles in a human glioblastoma. Oncogene. 16: 321-326, 1998.
15. Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A-C., and Van Meir, E. G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, and PTEN/ MMAC-1 tumor suppressor genes in human glioma cell lines. Brain Pathol., 9: 469-479, 1999.
16. Van Meir, E. G., Kikuchi, T., Tada, M., Li, H., Diserens, A. C., Wojcik, B. E., Huang, H. J. S., Friedmann, T., de Tribolet, N., and Cavenee, W. K. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res., 54: 649-652, 1994.
17. Harlow, E., and Lane, D. Antibodies. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1988.
18. Desbaillets, I., Diserens, A. C., Tribolet, N., Hamou, M. F., and Van Meir, E. G. Upregulation of inlerleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J. Exp. Med., 186: 1201-1212, 1997.
19. Herrero, M. E., Arand, M., Hengstler, J. G., and Oesch, F. Recombinant expression of human microsomal epoxide hydrolase protects V79 Chinese hamster cells from styrene oxide-but not from ethylene oxide-induced DNA strand breaks. Environ. Mol. Mutagen., 30: 429-439, 1997.
20. Kessler, R., Zacharova-Albinger, A., Laursen, N. B., Kalousek, M., and Klemenz, R. Attenuated expression of the serum responsive T1 gene in ras transformed fibroblasts due to the inhibition of c-fos activity. Oncogene. 18: 1733-1744, 1999.
21. El Deiry, W., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelsiein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
22. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
23. Madden, S. L. Galella, E. A., Riley, D., Bertelsen, A. H., and Beaudry, G. A. Induction of cell growth regulatory genes by p53. Cancer Res., 56: 5384-5390, 1996.
24. Weller, M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res., 292: 435-445, 1998.
25. Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W., and Bujard, H. Transcriptional activation by tetracyclines in mammalian cells. Science (Washington DC). 268: 1766-1769, 1995.
26. Doll, R., and Peto, R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst., 66: 1191-1308, 1981.
27. Manson, M. M. Epoxides-is there a human health problem? Br. J. Industrial Med., 37: 317-336, 1980.
28. Farber, E. Cellular biochemistry of the stepwise development of cancer with chemicals: G. H. A. Clowes memorial lecture. Cancer Res., 44: 5463-5474, 1984.
29. Benhamou, S., Reinikainen, M., Bouchardy, C., Dayer, P., and Hirvonen, A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res., 58: 5291-5293, 1998.
30. Lancaster, J. M., Brownlee, H. A., Bell. D. A., Futreal, P. A., Marks, J. R., Berchuck, A., Wisernan, R. W., and Taylor. J. A. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol. Carcinog., 17: 160-162, 1996.
31. McGlynn, K. A., Rosvold, E. A., Lustbader, E. D., Hu, Y., Clapper, M. L., Zhou, T., Wild, C. P., Xia, X. L., Baffoe Bonnie, A., Ofori Adjei, D., Chen, G-C., London, W. T., Shen, F-M., and Buetow, K. H. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc. Natl. Acad. Sci. USA, 92, 2384-2387, 1995.
32. Hassen, C., Aicher, L., Sidhu, J. S., and Omiecinski, C. J. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum. Mol. Genet., 3: 421-428, 1994.
33. Smith, C. A., and Harrison, D. J. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet, 350: 630-633, 1997.
34. Fulci, G., Ishii, N., and Van Meir, E. G. p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol., 8: 599-613, 1998.
35. Katakura, R., and Yoshimoto, T. Epidemiology and statistical analysis of gliomas. In: J. Suzuki (ed.) Treatment of Glioma, pp. 3-16. Berlin: Springer, 1988.
36. Waxweiler, R. J., Stringer, W., Wagoner, J. K., Jones. J., Falk, H., and Carter, C. Neoplastic risk among workers exposed to vinyl chloride. Ann. NY Acad. Sci., 271: 40-48, 1976.
37. Guengerich, F. P., Mason, P. S., Stott, W. T., Fox, T. R., and Watanabe, P. G. Roles of 2-haloethylene oxides and 2-haloacetaldehydes derived from vinyl bromide and vinyl chloride in irreversible binding to protein and DNA. Cancer Res., 41: 4391-4398, 1981.
38. Carr, B. I. Pleiotropic drug resistance in hepatocytes induced by carcinogens administered to rats. Cancer Res., 47: 5577-5583, 1987.
39. Ali, O. F., Caughlan, J., and Gray, G. S. Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1.3-bis(2-chloroethyl)-1-nitrosourea after in vitra reaction with glutathione. Cancer Res., 49: 5954-5958, 1989.
40. Grant, R., and Ironside, J. W. Glutathione S-transferases and cytochrome P450 detoxifying enzyme distribution in human cerebral glioma. J. Neurol. Oncol., 25: 1 -7, 1995.
41. Hara, A., Yamada, H., Sakai, N., Hirayama, H., Tanaka, T., and Mori, H. Immunohistochemical demonstration of the placental form of glutathione S-transferase, a detoxifying enzyme in human gliomas. Cancer (Phila.), 66: 2563-2568, 1990.
42. Shrikant, P., and Benveniste, E. N. The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation, J. Immunol., 157: 1819-1822, 1996.
43. Moghaddam, M. F., Grant, D. F., Cheek, J. M., Greene, J. F., Williamson, K. C., and Hammock, B. D. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase Nat. Med., 3: 562-566, 1997.
44. Rainov, N. G., Dobberstein, K. U., Sena, E. M., Herrlinger, U., Kramm, C. M., Philpot, R. M., Hilton, J., Chiocca, E. A., and Breakefield, X. O. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum. Gene Ther., 9: 1261-1273, 1998.
45. Morisseau, C., Goodrow, M. H., Dowdy, D., Zheng, J., Greene, J., Sanborn, J. R., and Hammock, B. D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad. Sci. USA, 96: 8849-8854, 1999.
46. Judy, K. D., Olivi, A., Buahin, K. G., Domb, A., Epstein, J. I., Colvin, O. M., and Brem. H. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J. Neurosurg., 82: 481-486, 1995.